Denmark - Pharmaceutical products

Description

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland.The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.
ATC Code: J01DH02Generic Name: MeropenemPharmaceutical form: Injection and infusion FluidStrenght: 500 mgPackage:Unit: 3 gVolume in units: (Denmark 4.014) (Norway: 3.133) (Iceland 233)ATC Code: J01DH02Generic Name: MeropenemPharmaceutical form: Injection and infusion FluidStrenght: 1000 mgPackage:Unit: 3 gVolume in units: (Denmark 195.780) (Norway: 72.511) (Iceland 5.933)Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.The Supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.The Pharmaceuticals shall be included in the Danish Medicines Agency’s list of medicine prices (‘medicinpriser.dk’) and the Norwegian ‘Farmalogg’ and the Icelandic ‘Lyfjaverðskrá’ not later than 21 February 2022 in order to ensure supply from the beginning of the purchase period.

Opportunity closing date

31 August 2021

Value of contract

£5m-50m